Biomarker Panel for CLL Subtype Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for characterizing chronic lymphocytic leukemia (CLL) are inadequate for prognosis and treatment selection due to limited understanding of the disease, leading to deficiencies in predicting disease progression and choosing appropriate therapies.
Innovation Solution
A panel of biomarkers, including specific polypeptide markers and their fragments or encoding polynucleotides, is used to characterize CLL, allowing for the classification of the disease into distinct expression subtypes, which guides prognosis and treatment selection through a method involving the measurement of marker levels in biological samples and classification using machine learning classifiers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If conventional characterization methods are used, then the analysis is simpler, but the understanding of CLL disease is insufficient leading to poor prognosis and treatment selection
Solution Approach 1:
The patent segments the CLL disease characterization into multiple distinct polypeptide markers (at least 2, preferably 5-20, up to 50 markers). Each marker provides specific information about different aspects of the disease, allowing comprehensive disease understanding through modular analysis of individual marker expressions rather than attempting to measure all disease features simultaneously.
Solution Approach 2:
The patent adds a new dimension to CLL characterization by introducing multi-dimensional phenotypic classification based on polypeptide marker expressions. This creates a comprehensive disease map that categorizes CLL into distinct subtypes, transforming the understanding from conventional single-parameter analysis to multi-parameter dimensional characterization that captures the heterogeneity of the disease.
2Measurement precision
If a comprehensive panel of markers is used, then the characterization accuracy is improved, but the measurement and analysis complexity increases
Solution Approach 1:
The patent employs universal detection methods that can measure multiple polypeptide markers simultaneously using the same assay platform and data analysis pipeline. This multi-functional approach allows accurate characterization of CLL by measuring many different markers with a single comprehensive test, avoiding the need for separate specialized assays for each marker and thereby reducing overall measurement complexity.
Solution Approach 2:
The patent uses polynucleotide sequences that encode the polypeptide markers as detectable proxies for the actual protein expressions. By measuring the presence and quantity of these genetic copies or transcripts, the system achieves accurate protein level characterization indirectly, simplifying the detection process while maintaining measurement precision.
3Reliability
If limited disease understanding is used, then the treatment selection is simpler, but the treatment effectiveness is reduced
Solution Approach 1:
The patent applies local quality by creating distinct phenotypic classifications for different subsets of CLL patients based on their specific polypeptide marker profiles. Rather than applying a single uniform treatment approach to all patients, the system identifies specific marker expression patterns (such as co-expression of particular marker pairs) and matches them with targeted therapies, ensuring that each patient receives treatment optimized for their specific disease characteristics.
Data Source
AI summary
As described below, the present invention features compositions, panels of biomarkers, and methods for characterizing chronic lymphocytic leukemia (CLL) for prognosis and selection of a subject for a treatment and/or inclusion in a clinical trial.